Home > Insider Trading > Filing (0000950170-24-042681)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1658247	Crinetics Pharmaceuticals Inc.	CRNX	Pharmaceutical Preparations (2834)	263744114

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1746298	Scott Richard Struthers	C/O Crinetics Pharmaceuticals, Inc. 6055 Lusk Boulevard San Diego CA 92121	President & Ceo	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-04-04	40,951	$9.28	278,786	No	4	M	Direct
Common Stock	Disposition	2024-04-04	40,951	$49.17	237,835	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-qualified stock option (Right to Buy)	Disposition	2024-04-04	40,951	$0.00	40,951	$9.28

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
123,790		2028-05-24	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	570,805	Indirect	By Family Trust 1
Common Stock	110,000	Indirect	By Family Trust 2
Common Stock	110,000	Indirect	By Family Trust 3
Common Stock	110,000	Indirect	By Family Trust 4
Common Stock	1,000	Indirect	By Spouse

Footnotes

The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan.
The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of $49.17 per share. The range of sales prices on the transaction date was $48.95 to $49.56 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.